Blog

19 Articles

Dr. Allyson Ocean
Treatments
April 14, 2023 • 5 Min

Who Should Be Screened For Pancreatic Cancer

Who should be screened for pancreatic cancer? Dr. Allyson Ocean explains how genetic mutations and family history factor into screening.

Dr. Ray Wadlow
Research
February 9, 2023 • 5 Min

PRECEDE Trial Sets Survival Rate Goal

Dr. Raymond Wadlow explains how the PRECEDE trial aims to increase pancreatic cancer survival through earlier detection of high-risk people.

Dr. Amitabh Chak
Symptoms
July 14, 2022 • 4 Min

New Gastrointestinal Screening Guidelines for High-Risk Patients

Gastroenterologist Dr. Amitabh Chak explains the new pancreatic cancer screening guidelines for high-risk people.

Kim Reiss Binder
Research
January 12, 2022 • 5 Min

New Study Aims to Reduce Recurrence Risk for Select Patients

Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.

multicolored abstract DNA against a black background
Research
April 29, 2021 • 3 Min

Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer

A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.

Dr. E. Gabriela Chiorean
Treatments
December 27, 2019 • 5 Min

Chemotherapy: A Key Player in the Battle Against Pancreatic Cancer

Dr. Gabriela Chiorean explains the different types of chemotherapy typically used to treat pancreatic cancer, and how they work.

glass test tubes in a cluster
Research
October 22, 2019 • 2 Min

Searching for Potential Pancreatic Cancer Blood Biomarkers

Researchers are using blood samples to follow people considered at risk for developing pancreatic cancer in a trial looking for early detection biomarkers.

Dr. Talia Golan
Research
March 26, 2019 • 4 Min

Damage as a Way to Repair Pancreatic Cancer

Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.

Draining board
Research
July 5, 2018 • 4 Min

A Potential Role for PARP Inhibitors in Pancreatic Cancer

Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.

DNA art built with wire and rainbow clear plastic
Research
June 26, 2018 • 2 Min

Early Detection Trial for People at Higher Risk of Pancreatic Cancer

Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.

DNA representation
Research
December 5, 2017 • 5 Min

The ABCs of Genetic Testing

There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.

Hands holding an image of DNA analysis, in blue light.
Treatments
December 1, 2017 • 6 Min

Before You Leap: Genetic Testing for Pancreatic Cancer

Genetic counselor Megan Frone outlines the advantages of genetic testing when there is a family history of pancreatic cancer.

Dr. Robert Kurtz
Research
September 18, 2017 • 4 Min

A Registry for Those at Risk for Pancreatic Cancer

Dr. Robert Kurtz founded the Pancreatic Tumor Registry at Memorial Sloan Kettering to learn more about the genetic mutations that cause pancreatic cancer.

Abstract image of DNA structure, with linked balls of greens on the left and reds and pinks on the right, forming a spiral net
Research
September 12, 2017 • 2 Min

New Drug for BRCA Carriers with Advanced Cancer

A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.

Illustration of a protein that includes the BRCA2 mutation. The illustration includes spirals in brown, strands in purple, blue directional arrows, and green, yellow, red, and blue circles.
Research
June 27, 2017 • 2 Min

A Maintenance Trial for Patients with BRCA or PALB2 Mutations

A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.

  • 1
  • 2